Want to see PVLA full AI Analyst Report?
Top Page
Palvella Therapeutics
(NASDAQ:PVLA)
Select Model
Select Model
Rating:62Neutral
Price Target:
$159.00
▲(22.30% Upside)
Action:Reiterated
Date:07/16/26
The score is held back primarily by weak financial performance (no current revenue, widening losses, and accelerating cash burn), despite balance-sheet flexibility from very low leverage. Offsetting that, technicals show a strong uptrend with constructive momentum, and corporate events are notably positive with Phase 3 success and clear NDA/launch milestones supported by substantial recent financing. Valuation remains a secondary headwind because profitability is negative and P/E is not meaningful.
Positive Factors
Regulatory Progress & Phase 3 Success
Robust, recent regulatory milestones and positive Phase 3 SELVA outcomes materially de-risk the lead program over the next 2–6 months. A rolling review and module submission signal a pathway to approval and commercialization, converting clinical value into sustainable revenue potential if full NDA and launch succeed.
Negative Factors
Pre-revenue Business Model
The company remains clinical-stage with no product revenue, meaning long-term viability depends on successful regulatory approval and commercialization. Until product sales commence, the business lacks operating revenue stability and is exposed to execution and clinical outcome risk across the approval horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory Progress & Phase 3 Success
Robust, recent regulatory milestones and positive Phase 3 SELVA outcomes materially de-risk the lead program over the next 2–6 months. A rolling review and module submission signal a pathway to approval and commercialization, converting clinical value into sustainable revenue potential if full NDA and launch succeed.
Read all positive factors
Palvella Therapeutics (PVLA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.12B
Dividend YieldN/A
Average Volume (3M)308.30K
Price to Earnings (P/E)―
Beta (1Y)-0.09
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.17
Shares Outstanding14,342,844
10 Day Avg. Volume192,423
30 Day Avg. Volume308,302
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$235.40Price Target Upside81.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.56
Revenue Forecast (FY)N/A
Palvella Therapeutics Business Overview & Revenue Model
Company Description
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to...
How the Company Makes Money
null...
Palvella Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 25.90M | 31.42M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 23.12M | 29.05M |
| EBITDA | -35.90M | -13.12M | 18.69M | -30.50M | -43.37M |
| Net Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M |
Balance Sheet | |||||
| Total Assets | 59.56M | 88.23M | 7.55M | 16.52M | 153.56M |
| Cash, Cash Equivalents and Short-Term Investments | 57.98M | 83.60M | 7.35M | 16.05M | 117.76M |
| Total Debt | 633.00K | 0.00 | 0.00 | 0.00 | 14.89M |
| Total Liabilities | 31.58M | 25.63M | 11.43M | 39.70M | 102.81M |
| Stockholders Equity | 27.98M | 62.61M | -3.88M | -23.17M | 50.76M |
Cash Flow | |||||
| Free Cash Flow | -25.01M | -10.84M | -13.70M | -14.84M | -8.61M |
| Operating Cash Flow | -25.01M | -10.84M | -13.70M | -14.84M | -7.66M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -949.00K |
| Financing Cash Flow | -660.00K | 87.09M | 5.00M | 9.57M | 59.13M |
Palvella Therapeutics Technical Analysis
Positive
130.01
Price Trends
125.08
Positive
125.75
Positive
105.88
Positive
Market Momentum
8.40
Negative
64.33
Neutral
80.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PVLA, the sentiment is Positive. The current price of 130.01 is below the 20-day moving average (MA) of 141.86, above the 50-day MA of 125.08, and above the 200-day MA of 105.88, indicating a bullish trend. The MACD of 8.40 indicates Negative momentum. The RSI at 64.33 is Neutral, neither overbought nor oversold. The STOCH value of 80.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PVLA.
Palvella Therapeutics Risk Analysis
Palvella Therapeutics disclosed 83 risk factors in its most recent earnings report. Palvella Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Palvella Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $879.53M | 7.48 | 43.85% | ― | 68.20% | ― | |
62 Neutral | $2.12B | -37.71 | -56.87% | ― | ― | ― | |
59 Neutral | $2.39B | -6.70 | -64.21% | ― | -58.40% | -31.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.88B | -14.74 | -42.66% | ― | ― | -33.07% | |
49 Neutral | $726.98M | -53.68 | -12.84% | ― | ― | 40.38% |
* Healthcare Sector Average
PVLA
Palvella Therapeutics
157.24
127.73
432.84%
TBPH
Theravance Biopharma
16.93
5.68
50.49%
MNPR
Monopar Therapeutics Inc
111.12
64.64
139.07%
NRIX
Nurix Therapeutics
23.12
11.91
106.24%
TYRA
Tyra Bioscience
32.13
21.74
209.24%
Palvella Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
Positive
Jul 15, 2026
On July 14, 2026, Palvella Therapeutics posted a new corporate presentation outlining its progress and growth plans, anchored by the QTORIN 3.9% rapamycin anhydrous gel program for microcystic lymphatic malformations. The company reported positive...
Business Operations and StrategyExecutive/Board Changes
Palvella Therapeutics Adds Industry Veteran to Board
Positive
Jun 30, 2026
On June 29, 2026, Palvella Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed industry veteran Matthew Pauls as a Class I director, with his initial term running until the 2027 Annual Meeting of Stockholde...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
Positive
Jun 16, 2026
On June 10, 2026, at its Annual Meeting of Stockholders, Palvella Therapeutics’ investors approved an amendment to the 2024 Equity Incentive Plan, increasing the authorized shares available for issuance by 750,000, a move that expands the co...
Business Operations and StrategyProduct-Related Announcements
Palvella Reports Positive Phase 3 Data for QTORIN
Positive
May 20, 2026
On May 20, 2026, Palvella Therapeutics reported new positive Phase 3 SELVA and Phase 2 TOIVA clinical data for its topical QTORIN rapamycin gel at the International Society for the Study of Vascular Anomalies World Congress 2026 in Philadelphia, u...
Business Operations and StrategyProduct-Related Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
Positive
May 15, 2026
On May 15, 2026, Palvella Therapeutics reported new data from its Phase 2 TOIVA trial of topical QTORIN rapamycin in cutaneous venous malformations, presented at the 83rd Annual Meeting of the Society for Investigative Dermatology in Chicago. The ...
Delistings and Listing Changes
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
Positive
May 13, 2026
On May 11, 2026, Palvella Therapeutics, Inc. announced that it had received approval from the Nasdaq Listing Qualifications Department to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market. The move, effec...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
Palvella Highlights QTORIN Progress and Financing in Q1 Update
Positive
May 7, 2026
On May 7, 2026, Palvella Therapeutics reported first-quarter 2026 results and a broad corporate update, highlighting positive Phase 3 SELVA data for QTORIN rapamycin in microcystic lymphatic malformations, a granted FDA pre‑NDA meeting in th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.